ANSES Audits High-Risk Supplement Actives Flagged by French Nutrivigilance
France's food safety agency ANSES has launched a literature review into supplement ingredients flagged for adverse events. The findings will form the technical basis for impending national restrictions and EU Article 8 scrutiny.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Maisons-Alfort, France — 27 October 2026
France’s food safety agency, ANSES, has initiated a comprehensive scientific literature review targeting food supplement ingredients flagged as concerning by its national nutrivigilance scheme. Operating through the agency’s Risk Assessment Department (Direction de l'évaluation des risques) under reference STAGE 2026-028, the project will consolidate clinical and toxicological evidence on actives associated with adverse health events.
The Nutrivigilance scheme acts as France's primary surveillance mechanism for tracking adverse reactions associated with food supplements, fortified products, and novel foods. When clinical signals indicate recurring hepatic, cardiovascular, or neurological side effects, ANSES conducts targeted literature evaluations to establish risk profiles. Historically, these reviews serve as the technical foundation for binding national restrictions and European Commission Article 8 referrals. When nutrivigilance data points to acute safety signals, the agency compiles peer-reviewed toxicological data to establish safe exposure thresholds, routinely leading to revised conditions of use or outright ingredient bans.
Precedent indicates that ANSES reviews systematically precede statutory market interventions. Previous agency investigations directly prompted stringent daily consumption caps, mandatory label warnings, and targeted bans on substances such as hydroxyanthracene derivatives, red yeast rice, and high-bioavailability curcumin extracts. By compiling published literature on flagged substances now, the agency is actively building the safety dossiers that determine whether commercial actives require inclusion on restricted substance lists.
What this means for France
Brand owners retailing across French pharmacy networks and health retailers must audit formulation portfolios immediately. Actives under nutrivigilance scrutiny carry a high probability of regulatory intervention within a 12- to 18-month timeline, posing severe inventory obsolescence risks. Contract manufacturers and formulation teams should identify alternative botanical extracts before the French Directorate General for Competition Policy, Consumer Affairs and Fraud Control (DGCCRF) enacts formal restrictions. Reformulating complex botanical finished goods requires 14- to 16-week lead times and laboratory stability budgets of €5,000 to €15,000 per product. Brands that preemptively adjust dosages protect pharmacy shelf space and streamline compliance notifications on the French TéléIcare registry.
Many leading brands in this category are manufactured in partnership with Supplement Factory.